Cargando…
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Objective. To assess the efficacy of rituximab (RTX) in SSc. Methods. Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, w...
Autores principales: | Daoussis, Dimitrios, Liossis, Stamatis-Nick C., Tsamandas, Athanassios C., Kalogeropoulou, Christina, Kazantzi, Alexandra, Sirinian, Chaido, Karampetsou, Maria, Yiannopoulos, Georgios, Andonopoulos, Andrew P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806066/ https://www.ncbi.nlm.nih.gov/pubmed/19447770 http://dx.doi.org/10.1093/rheumatology/kep093 |
Ejemplares similares
-
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin
por: Daoussis, Dimitrios, et al.
Publicado: (2012) -
B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence
por: Daoussis, Dimitrios, et al.
Publicado: (2011) -
B cells tell scleroderma fibroblasts to produce collagen
por: Daoussis, Dimitrios, et al.
Publicado: (2013) -
B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis
por: Daoussis, Dimitrios, et al.
Publicado: (2016) -
Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions
por: Daoussis, Dimitrios, et al.
Publicado: (2019)